Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery

Biomaterials

Volumn 31, Issue 5, 2010, Pages 952-963

  Zhang, Sufeng ^a   Kucharski, Cezary ^a   Doschak, Michael R ^a   Sebald, Walter ^b   Uludaǧ, Hasan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Bone morphogenetic protein 2; Bovine serum albumin; Ectopic bone formation; In vivo; Nanoparticle; Polyethylenimine PEG

Indexed keywords

BONE MORPHOGENETIC PROTEIN-2; BOVINE SERUM ALBUMINS; ECTOPIC BONES; IN-VIVO; POLYETHYLENIMINES;

BIOCOMPATIBILITY; BODY FLUIDS; BONE; COATINGS; ETHYLENE; ETHYLENE GLYCOL; NANOPARTICLES; POLYETHYLENE OXIDES; PROTEINS; TOXICITY; ZETA POTENTIAL;

POLYETHYLENE GLYCOLS;

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; BOVINE SERUM ALBUMIN; MACROGOL; POLYETHYLENEIMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RETENTION; HUMAN; HUMAN CELL; IN VIVO STUDY; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; OSSIFICATION; PARTICLE SIZE; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; COATED MATERIALS, BIOCOMPATIBLE; DRUG CARRIERS; FEMALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; OSTEOGENESIS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN; TISSUE DISTRIBUTION;

BOVINAE; RATTUS;

EID: 70649083100     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.10.011     Document Type: Article

References (59)

1. Bessa P.C., Casal M., and Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2 (2008) 81-96
2. Barboza E.P., Duarte M.E.L., Geolas L., Sorensen R.G., Riedel G.E., and Wikesjö U.M.E. Ridge augmentation following implantation of recombinant human bone morphogenetic protein-2 in the dog. J Periodontol 71 (2000) 488-496
3. Boyne P.J. Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J Bone Joint Surg Am 83 (2001) S146-S150
4. Chen B., Lin H., Wang J., Zhao Y., Wang B., Zhao W., et al. Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2. Biomaterials 28 (2007) 1027-1035
5. Levine J., Bradley J., Turk A.E., Ricci J.L., Benedict J.J., Steiner G., et al. Bone morphogenetic protein promotes vascularization and osteoinduction in preformed hydroxyapatite in the rabbit. Ann Plast Surg 39 (1997) 158-168
6. Ripamonti U., Ramoshebi L.N., Matsaba T., Tasker J., Crooks J., and Teare J. Bone induction by BMPs/OPs and related family members in primates: the critical role of delivery systems. J Bone Joint Surg Am 83 (2001) S116-S127
7. Sandhu H.S., and Khan S.N. Animal models for preclinical assessment of bone morphogenetic proteins in the spine. Spine 27 (2002) S32-S38
8. Wozney J.M.P., and Rosen V.P. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 346 (1998) 26-37
9. Boden S.D., Zdeblick T.A., Sandhu H.S., and Heim S.E. The use of rhBMP-2 in interbody fusion cages. Spine 25 (2000) 376-381
10. Boden S.D., Martin G.J.J., Morone M.A., Ugbo J.L., and Moskovitz P.A. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein-2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine 24 (1999) 1179
11. Boden S.D. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine 27 (2002) S26-S31
12. Baskin D.S., Ryan P., Sonntag V., Westmark R., and Widmayer M. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR™ allograft ring and the ATLANTIS™ anterior cervical plate. Spine 28 (2003) 1219-1224
13. Cook S.D. Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites. Orthopedics 22 (1999) 669-671
14. Friedlaender G.E., Perry C.R., Cole J.D., Cook S.D., Cierny G., Muschler G.F., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions - a prospective, randomized clinical trial comparing rhOP-1 with fresh bone autograft. J Bone Joint Surg Am 83A (2001) S151-S158
15. Dinopoulos H., and Giannoudis P.V. The use of bone morphogenetic proteins (BMPs) in long-bone non-unions. Curr Orthop 21 (2007) 268-279
16. Wang E.A. Bone morphogenetic proteins (BMPs): therapeutic potential in healing bony defects. Trends Biotechnol 11 (1993) 379-383
17. Sykaras N., and Opperman L.A. Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician?. J Oral Sci 45 (2003) 57-73
18. Uludaǧ H., D'Augusta D., Palmer R., Timony G., and Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res 46 (1999) 193-202
19. Uludaǧ H., D'Augusta D., Golden J., Li J., Timony G., Riedel R., et al. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J Biomed Mater Res 50 (2000) 227-238
20. Uludaǧ H., Gao T., Porter T.J., Friess W., and Wozney J.M. Delivery systems for BMPs: factors contributing to protein retention at an application site. J Bone Joint Surg Am 83 (2001) S128-S135
21. Lane J.M. BMPs: why are they not in everyday use?. J Bone Joint Surg Am 83 (2001) S161-S162
22. Luginbuehl V., Meinel L., Merkle H.P., and Gander B. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm 58 (2004) 197-208
23. Kim S.E., Jeon O., Lee J.B., Bae M.S., Chun H.J., Moon S.H., et al. Enhancement of ectopic bone formation by bone morphogenetic protein-2 delivery using heparin-conjugated PLGA nanoparticles with transplantation of bone marrow-derived mesenchymal stem cells. J Biomed Sci 15 (2008) 771-777
24. Zhang S., Wang G., Lin X., Chatzinikolaidou M., Jennissen H., Laub M., et al. Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery. Biotechnol Prog 24 (2008) 945-956
25. Wang G., Siggers K., Zhang S., Jiang H., Xu Z., Zernicke R.F., et al. Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 25 (2008) 2896-2909
26. Yigor P., Tuzlakoglu K., Reis R.L., Hasirci N., and Hasirci V. Incorporation of a sequential BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering. Biomaterials 30 (2009) 3551-3559
27. Chung Y.I., Ahn K.M., Jeon S.H., Lee S.Y., Lee J.H., and Tae G. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J Control Release 121 (2007) 91-99
28. Zhang S., Doschak M.R., and Uludaǧ H. Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine-coated albumin nanoparticles. Biomaterials 30 (2009) 5143-5155
29. Pathak Y., Thassu D., and Deleers M. Pharmaceutical applications of nanoparticulate drug-delivery systems. In: Thassu D., Deleers M., and Pathak Y. (Eds). Nanoparticulate drug delivery systems (2007), Informa Healthcare, New York 185-212
30. Hermanson G.T. Modification with synthetic polymers. Bioconjugate techniques (1996), Academic Press, San Diego 605-629
31. Hinds K.D. Protein conjugation, cross-linking and PEGylation. In: Mahato R.I. (Ed). Biomaterials for delivery and targeting of proteins and nucleic acids (2005), CRC Press, Boca Raton 120-188
32. Zhang S., Wright J.E.I., Özber N., and Uludaǧ H. The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite. Macromol Biosci 7 (2007) 656-670
33. Ruppert R., Hoffmann E., and Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 237 (1996) 295-302
34. Perrine T.D., and Landis W.R. Analysis of polyethylenimine by spectrophotometry of its copper chelate. J Polym Sci 5 (1967) 1993-2003
35. Von Harpe A., Petersen H., Li Y., and Kissel T. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J Control Release 69 (2000) 309-322
36. Bullock J., Chowdhury S., Severdia A., Sweeney J., Johnston D., and Pachla L. Comparison of results of various methods used to determine the extent of modification of methoxy polyethylene glycol 5000-modified bovine cupri-zinc superoxide dismutase. Anal Biochem 254 (1997) 254-262
37. Gittens S.A., Bansal G., Kucharski C., Borden M., and Uludaǧ H. Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes. Mol Pharm 2 (2005) 392-406
38. Varkey M., Kucharski C., Haque T., Sebald W., and Uludaǧ H. In vitro osteogenic response of rat bone marrow cells to bFGF and BMP-2 treatments. Clin Orthop Relat Res 443 (2006) 113-123
39. Hiemenz P.C., and Rajagopalan R. Electrostatic and polymer-induced colloid stability. Principles of colloid and surface chemistry. 3rd ed. (1997), Marcel Dekker, New York 604-610
40. Winn S.R., Uludaǧ H., and Hollinger J.O. Carrier systems for bone morphogenetic proteins. Clin Orthop Relat Res 367 (1999) S95-106
41. LeGeros R.Z. Properties of osteoconductive biomaterials: calcium phosphates. Clin Orthop Relat Res 395 (2002) 81-98
42. Baldwin S.P., and Saltzman W.M. Materials for protein delivery in tissue engineering. Adv Drug Deliv Rev 33 (1998) 71-86
43. Petersen H., Fechner P.M., Martin A.L., Kunath K., Stolnik S., Roberts C.J., et al. Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjug Chem 13 (2002) 845-854
44. Tang G.P., Zeng J.M., Gao S.J., Ma Y.X., Shi L., Li Y., et al. Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent. Biomaterials 24 (2003) 2351-2362
45. Kunath K., Von Harpe A., Petersen H., Fischer D., Voigt K., Kissel T., et al. The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kB decoy in mice. Pharm Res 19 (2002) 810-817
46. Remaut K., Lucas B., Raemdonck K., Braeckmans K., Demeester J., and De Smedt S.C. Protection of oligonucleotides against enzymatic degradation by pegylated and nonpegylated branched polyethyleneimine. Biomacromolecules 8 (2007) 1333-1340
47. Niidome T., Yamagata M., Okamoto Y., Akiyama Y., Takahashi H., Kawano T., et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 114 (2006) 343-347
48. Bazile D., Prud'homme C., Bassoullet M.T., Marlard M., Spenlehauer G., Veillard M., et al. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 84 (1995) 493-498
49. Waku T., Matsusaki M., Kaneko T., and Akashi M. PEG brush peptide nanospheres with stealth properties and chemical functionality. Macromolecules 40 (2007) 6385-6392
50. Helm G.A., Sheehan J.M., Sheehan J.P., Jane J.A., Dipierro C.G., Simmons N.E., et al. Utilization of type I collagen gel, demineralized bone matrix, and bone morphogenetic protein-2 to enhance autologous bone lumbar spinal fusion. J Neurosurg 86 (1997) 93-100
51. Takahashi Y., Yamamoto M., and Tabata Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and β-tricalcium phosphate. Biomaterials 26 (2005) 4856-4865
52. Mishra V., Mahor S., Rawat A., Gupta P.N., Dubey P., Khatri K., et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 14 (2006) 45-53
53. Winn S.R., Uludaǧ H., and Hollinger J.O. Sustained release emphasizing recombinant human bone morphogenetic protein-2. Adv Drug Deliv Rev 31 (1998) 303-318
54. Wei G., Jin Q., Giannobile W.V., and Ma P.X. The enhancement of osteogenesis by nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. Biomaterials 28 (2007) 2087-2096
55. Chen F.M., Zhao Y.M., Zhang R., Jin T., Sun H.H., Wu Z.F., et al. Periodontal regeneration using novel glycidyl methacrylated dextran (Dex-GMA)/gelatin scaffolds containing microspheres loaded with bone morphogenetic proteins. J Control Release 121 (2007) 81-90
56. Fan H., Hu Y., Qin L., Li X., Wu H., and Lv R. Porous gelatin-chondroitin-hyaluronate tri-copolymer scaffold containing microspheres loaded with TGF-beta1 induces differentiation of mesenchymal stem cells in vivo for enhancing cartilage repair. J Biomed Mater Res 77A (2006) 785-794
57. Rengachary S.S. Bone morphogenetic proteins: basic concepts. Neurosurg Focus 13 (2002) 1-6
58. Zhao B., Katagiri T., Toyoda H., Takada T., Yanai T., Fukuda T., et al. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 281 (2006) 23246-23253
59. Westerhuis R.J., Van Bezooijen R.L., and Klloen P. Use of bone morphogenetic proteins in traumatology. Injury 36 (2005) 1405-1412